Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Total Current Liabilities (2017 - 2021)

Cogent Biosciences has reported Total Current Liabilities over the past 5 years, most recently at $16.7 million for Q3 2021.

  • Quarterly results put Total Current Liabilities at $16.7 million for Q3 2021, down 16.96% from a year ago — trailing twelve months through Sep 2021 was $16.7 million (down 16.96% YoY), and the annual figure for FY2020 was $13.1 million, down 1.16%.
  • Total Current Liabilities for Q3 2021 was $16.7 million at Cogent Biosciences, up from $13.7 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for COGT hit a ceiling of $26.4 million in Q3 2018 and a floor of $8.2 million in Q1 2021.
  • Median Total Current Liabilities over the past 5 years was $18.4 million (2020), compared with a mean of $18.0 million.
  • Biggest five-year swings in Total Current Liabilities: surged 122.92% in 2018 and later plummeted 65.98% in 2020.
  • Cogent Biosciences' Total Current Liabilities stood at $11.2 million in 2017, then surged by 122.92% to $24.9 million in 2018, then tumbled by 46.89% to $13.2 million in 2019, then fell by 1.16% to $13.1 million in 2020, then increased by 27.61% to $16.7 million in 2021.
  • The last three reported values for Total Current Liabilities were $16.7 million (Q3 2021), $13.7 million (Q2 2021), and $8.2 million (Q1 2021) per Business Quant data.